Glenmark Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 15 Feb 2025
Result Summary
- Glenmark Pharmaceuticals Ltd reported a 1.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 34.0%.
- Its expenses for the quarter were down by 1.3% QoQ and 1.1% YoY.
- The net profit decreased 1.8% QoQ and decreased 205.2% YoY.
- The earnings per share (EPS) of Glenmark Pharmaceuticals Ltd stood at 12.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3418.68 | 3473.21 | 2552.11 | -1.6% | 34.0% |
Total Expenses | 2962.35 | 3000.64 | 2996.77 | -1.3% | -1.1% |
Profit Before Tax | 456.33 | 472.57 | -521.38 | -3.4% | -187.5% |
Tax | 108.30 | 118.09 | -71.80 | -8.3% | -250.8% |
Profit After Tax | 348.03 | 354.48 | -330.82 | -1.8% | -205.2% |
Earnings Per Share | 12.30 | 12.60 | -12.40 | -2.4% | -199.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Glenmark Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of branded and generic formulations. The company operates across multiple therapeutic areas including dermatology, respiratory, and oncology. Glenmark has a significant presence in both domestic and international markets, offering a diverse range of pharmaceutical products. As of the latest updates, Glenmark has been focusing on expanding its research and development capabilities to strengthen its product pipeline. There are no specific major developments highlighted within the data provided, so any recent strategic shifts or innovations are not detailed in this analysis.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Glenmark Pharmaceuticals Ltd reported a total income of ₹3418.68 crores. This represents a quarterly decrease of 1.6% compared to the previous quarter (Q2FY25), where the total income was ₹3473.21 crores. On a year-over-year basis, there was a notable increase in total income by 34.0% from the ₹2552.11 crores reported in the third quarter of the fiscal year 2024 (Q3FY24). This significant year-over-year growth reflects the company's strengthened position in its market segments, although specific drivers of this increase are not detailed in the data provided.
Profitability
Glenmark Pharmaceuticals Ltd reported a profit before tax of ₹456.33 crores in Q3FY25, which marks a decrease of 3.4% from the ₹472.57 crores achieved in Q2FY25. When looking at the year-over-year comparison, the profit before tax improved significantly from a negative ₹521.38 crores in Q3FY24. Similarly, the profit after tax for Q3FY25 stood at ₹348.03 crores, showing a slight quarterly decrease of 1.8% from ₹354.48 crores in Q2FY25. However, this is a substantial improvement from a net loss of ₹330.82 crores recorded in Q3FY24. The company's earnings per share (EPS) for Q3FY25 was ₹12.30, down 2.4% from ₹12.60 in the previous quarter, yet significantly better than the negative EPS of ₹-12.40 recorded in the same quarter of the previous year.
Operating Metrics
The total expenses for Glenmark Pharmaceuticals Ltd in Q3FY25 were ₹2962.35 crores, reflecting a decrease of 1.3% from ₹3000.64 crores in Q2FY25. When compared to Q3FY24, there is a slight reduction of 1.1% from ₹2996.77 crores. The tax expense for the third quarter of FY25 was ₹108.30 crores, which is an 8.3% decrease from the ₹118.09 crores observed in the previous quarter and a significant turnaround from the negative tax figure of ₹-71.80 crores in Q3FY24. These figures highlight a stabilization in the company's expense management and tax obligations over the past year, although specific strategies or factors contributing to these changes are not detailed in the data provided.
